4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Pharvaris N.V. (PHVS) operates in the Biotechnology industry and is headquartered in Zug, Switzerland with about 134 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, PHVS reported $0M in revenue and ($176M) in net income.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($170M) | ($146M) | ($97M) | ($87M) | — |
| Net Income | ($176M) | ($134M) | ($101M) | ($76M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($44M) | ($48M) | ($40M) | ($40M) | ($42M) | — |
| Net Income | ($39M) | ($47M) | ($37M) | ($46M) | ($46M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $302M | $291M | $399M | $168M | — |
| Total Liabilities | $30M | $24M | $15M | $18M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHVS viewer.
About TickerBase · Data methodology & sources